Close Menu

NEW YORK – Edison Oncology said last week that it has out-licensed the worldwide rights to its DNA damage response inhibitors and EO2000 PARP inhibitor technology program to Rakovina Therapeutics.

Edison's assets are in line with Vancouver-based Rakovina's focus on developing cancer treatments using novel DNA damage response technologies. In exchange for the rights to Edison's drugs and the EO2000 program, Rakovina has issued 43 percent of its outstanding common shares to Edison subsidiary NewGen Therapeutics.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.